Prospective evaluation of detection of circulating tumor DNA (ctDNA) to predict recurrence after definitive therapy of localized stage lung cancer (PREDICT)
Recruiting
- Conditions
- lung cancer nsclc and sclc
- Registration Number
- DRKS00016416
- Lead Sponsor
- Klinik für Kardiologie und Pneumologie, Klinikum Esslingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Patients with NSCLC stage I-IVA with planned curative therapy. SCLC stage I-IIIC with planned curative therapy.
Exclusion Criteria
None
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurence-free survival at 1, 2, 3, 5 years post-therapeutically.
- Secondary Outcome Measures
Name Time Method Overall-survival